-
1
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
2
-
-
79958043675
-
-
National Cancer Institute. Bethesda, MD based on November 2014 SEER data submission, posted to the SEER web site, April 2015
-
Howlader N NA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, et al. (editors). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, Available from: http://seer.cancer.gov/csr/1975-2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
-
SEER Cancer Statistics Review 1975-2012
-
-
Howlader, N.N.A.1
Krapcho, M.2
Garshell, J.3
Miller, D.4
Altekruse, S.F.5
Kosary, C.L.6
-
3
-
-
67649886201
-
Potent antibody drug conjugates for cancer therapy
-
Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
-
(2009)
Curr Opin Chem Biol
, vol.13
, pp. 235-244
-
-
Senter, P.D.1
-
4
-
-
84906874906
-
Ado-Trastuzumab emtansine (T-DM1): An antibodydrug conjugate (ADC) for HER2-positive breast cancer
-
Lambert JM, Chari RV. Ado-Trastuzumab emtansine (T-DM1): An antibodydrug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
-
(2014)
J Med Chem
, vol.57
, pp. 6949-6964
-
-
Lambert, J.M.1
Chari, R.V.2
-
5
-
-
84863688504
-
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
-
Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
-
(2012)
Nat Biotechnol
, vol.30
, pp. 631-637
-
-
Senter, P.D.1
Sievers, E.L.2
-
7
-
-
84934444640
-
Antibody-drug conjugate (ADC) clinical pipeline: A review
-
Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: A review. Methods Mol Biol 2013;1045:1-27.
-
(2013)
Methods Mol Biol
, vol.1045
, pp. 1-27
-
-
Sassoon, I.1
Blanc, V.2
-
8
-
-
84963814117
-
Current approaches for ADME characterization of antibody-drug conjugates: An industry white paper
-
Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, et al. Current approaches for ADME characterization of antibody-drug conjugates: An industry white paper. Drug Metab Dispos 2015;44:617-23.
-
(2015)
Drug Metab Dispos
, vol.44
, pp. 617-623
-
-
Kraynov, E.1
Kamath, A.V.2
Walles, M.3
Tarcsa, E.4
Deslandes, A.5
Iyer, R.A.6
-
11
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
-
MaedaH, Wu J, Sawa T, Matsumura Y, Hori K.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84.
-
(2000)
J Control Release
, vol.65
, pp. 271-284
-
-
Maedah Wu, J.1
Sawa, T.2
Matsumura, Y.3
Hori, K.4
-
12
-
-
34247391483
-
Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
-
Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007;10:59-67.
-
(2007)
Drug Resist Updat
, vol.10
, pp. 59-67
-
-
Fojo, T.1
-
14
-
-
84890018871
-
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
-
Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-96.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3987-3996
-
-
Gainor, J.F.1
Shaw, A.T.2
-
15
-
-
84962207990
-
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
-
Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat 2016;26:1-9.
-
(2016)
Drug Resist Updat
, vol.26
, pp. 1-9
-
-
Fletcher, J.I.1
Williams, R.T.2
Henderson, M.J.3
Norris, M.D.4
Haber, M.5
-
16
-
-
33644977169
-
Paclitaxelresistant cells have a mutation in the paclitaxel-binding region of betatubulin (Asp26Glu) and less stable microtubules
-
Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, et al. Paclitaxelresistant cells have a mutation in the paclitaxel-binding region of betatubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-8.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 270-278
-
-
Hari, M.1
Loganzo, F.2
Annable, T.3
Tan, X.4
Musto, S.5
Morilla, D.B.6
-
17
-
-
7444224866
-
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha-or beta-Tubulin and increased microtubule stability
-
Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, et al. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha-or beta-Tubulin and increased microtubule stability. Biochemistry 2004;43:13944-54.
-
(2004)
Biochemistry
, vol.43
, pp. 13944-13954
-
-
Poruchynsky, M.S.1
Kim, J.H.2
Nogales, E.3
Annable, T.4
Loganzo, F.5
Greenberger, L.M.6
-
18
-
-
77649191871
-
Microtubules and resistance to tubulin-binding agents
-
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 194-204
-
-
Kavallaris, M.1
-
20
-
-
0025901097
-
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide
-
Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A 1991;88:7654-8.
-
(1991)
Proc Natl Acad Sci U S A
, vol.88
, pp. 7654-7658
-
-
Bugg, B.Y.1
Danks, M.K.2
Beck, W.T.3
Suttle, D.P.4
-
21
-
-
0036830256
-
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
-
Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
-
(2002)
Cancer Res
, vol.62
, pp. 6141-6145
-
-
Grunwald, V.1
DeGraffenried, L.2
Russel, D.3
Friedrichs, W.E.4
Ray, R.B.5
Hidalgo, M.6
-
22
-
-
84908251818
-
Poised epigenetic states and acquired drug resistance in cancer
-
Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer 2014;14:747-53.
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 747-753
-
-
Brown, R.1
Curry, E.2
Magnani, L.3
Wilhelm-Benartzi, C.S.4
Borley, J.5
-
23
-
-
84980367693
-
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
-
Wijdeven RH, Pang B, Assaraf YG, Neefjes J. Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics. Drug Res Updat 2016;28: 65-81.
-
(2016)
Drug Res Updat
, vol.28
, pp. 65-81
-
-
Wijdeven, R.H.1
Pang, B.2
Assaraf, Y.G.3
Neefjes, J.4
-
25
-
-
84906091148
-
Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines [abstract]
-
Apr 5-9; San Diego, CA: Philadelphia (PA): AACR 2014 Abstract 688
-
Lewis TS, Gordon K, Li F, Weimann A, Bruders R, Miyamoto JB, et al. Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA: Philadelphia (PA): AACR; 2014. Abstract 688.
-
(2014)
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research
-
-
Lewis, T.S.1
Gordon, K.2
Li, F.3
Weimann, A.4
Bruders, R.5
Miyamoto, J.B.6
-
26
-
-
84942114899
-
CD30 downregulation MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin
-
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 2015;14: 1376-84.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 1376-1384
-
-
Chen, R.1
Hou, J.2
Newman, E.3
Kim, Y.4
Donohue, C.5
Liu, X.6
-
27
-
-
84941656661
-
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
-
Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 2015;14:952-63.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 952-963
-
-
Loganzo, F.1
Tan, X.2
Sung, M.3
Jin, G.4
Myers, J.S.5
Melamud, E.6
-
28
-
-
0025688250
-
Vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates
-
Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990;50: 7634-40.
-
(1990)
Cancer Res
, vol.50
, pp. 7634-7640
-
-
Starling, J.J.1
Maciak, R.S.2
Hinson, N.A.3
Hoskins, J.4
Laguzza, B.C.5
Gadski, R.A.6
-
29
-
-
84942905381
-
A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs
-
Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res 2015;21:3298-306.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3298-3306
-
-
Yu, S.F.1
Zheng, B.2
Go, M.3
Lau, J.4
Spencer, S.5
Raab, H.6
-
30
-
-
84958768935
-
A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-Targeted therapy
-
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-Targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-Targeted therapy. Cancer Cell 2016;29:117-29.
-
(2016)
Cancer Cell
, vol.29
, pp. 117-129
-
-
Li, J.Y.1
Perry, S.R.2
Muniz-Medina, V.3
Wang, X.4
Wetzel, L.K.5
Rebelatto, M.C.6
-
31
-
-
85008332533
-
Creating a superior site-specific anti-HER2 antibody-drug conjugate (NGHER2 ADC) for treatment of solid tumors [abstract]
-
Apr 16-20; New Orleans, LA.; New Orleans, LA: Philadelphia (PA): AACR 2016. Abstract 868
-
Ma D, Narayanan B, Marquette K, Graziani E, Loganzo F, Charati M, et al. Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NGHER2 ADC) for treatment of solid tumors [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.; New Orleans, LA: Philadelphia (PA): AACR; 2016. Abstract 868.
-
(2016)
Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research
-
-
Ma, D.1
Narayanan, B.2
Marquette, K.3
Graziani, E.4
Loganzo, F.5
Charati, M.6
-
32
-
-
12344302247
-
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
-
Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1585-1592
-
-
Tanner, M.1
Kapanen, A.I.2
Junttila, T.3
Raheem, O.4
Grenman, S.5
Elo, J.6
-
33
-
-
84860389569
-
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
-
Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011;13:R46.
-
(2011)
Breast Cancer Res
, vol.13
, pp. R46
-
-
Barok, M.1
Tanner, M.2
Koninki, K.3
Isola, J.4
-
34
-
-
85008396460
-
Emergingmechanisms of resistance to antibody drug conjugates in preclinical models
-
Feb 18; San Francisco, CA: Molecular Med Tri-Con
-
Loganzo F, Sung M, Tan X, Gerber HP. Emergingmechanisms of resistance to antibody drug conjugates in preclinical models. MolecularMed Tri-Con; 2015 Feb 18; San Francisco, CA: Molecular Med Tri-Con.
-
(2015)
MolecularMed Tri-Con
-
-
Loganzo, F.1
Sung, M.2
Tan, X.3
Gerber, H.P.4
-
35
-
-
73949135792
-
Mechanisms of multidrug resistance in cancer
-
Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010;596:47-76.
-
(2010)
Methods Mol Biol
, vol.596
, pp. 47-76
-
-
Gillet, J.P.1
Gottesman, M.M.2
-
36
-
-
77950224905
-
Antibody-maytansinoid conjugates designed to bypass multidrug resistance
-
Kovtun YV, Audette CA, MayoMF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.
-
(2010)
Cancer Res
, vol.70
, pp. 2528-2537
-
-
Kovtun, Y.V.1
Audette, C.A.2
Mayo, M.F.3
Jones, G.E.4
Doherty, H.5
Maloney, E.K.6
-
37
-
-
84922269141
-
Antibody-Targeted drugs and drug resistance-challenges and solutions
-
Shefet-Carasso L, Benhar I. Antibody-Targeted drugs and drug resistance-challenges and solutions. Drug Resist Updat 2015;18:36-46.
-
(2015)
Drug Resist Updat
, vol.18
, pp. 36-46
-
-
Shefet-Carasso, L.1
Benhar, I.2
-
38
-
-
34248338806
-
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
-
Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-70.
-
(2007)
Blood
, vol.109
, pp. 4168-4170
-
-
Walter, R.B.1
Gooley, T.A.2
Van Der Velden, V.H.3
Loken, M.R.4
Van Dongen, J.J.5
Flowers, D.A.6
-
39
-
-
78651378808
-
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: Mechanisms of action and resistance, safety and efficacy
-
Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 2011;11:225-34.
-
(2011)
Expert Opin Biol Ther
, vol.11
, pp. 225-234
-
-
Breccia, M.1
Lo-Coco, F.2
-
40
-
-
84881342420
-
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): The experience of gemtuzumab ozogamicin
-
Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): The experience of gemtuzumab ozogamicin. Ann Ist Super Sanita 2013;49:150-68.
-
(2013)
Ann Ist Super Sanita
, vol.49
, pp. 150-168
-
-
Cianfriglia, M.1
-
41
-
-
33644775686
-
Targeting multidrug resistance in cancer
-
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5: 219-34.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 219-234
-
-
Szakacs, G.1
Paterson, J.K.2
Ludwig, J.A.3
Booth-Genthe, C.4
Gottesman, M.M.5
-
43
-
-
67650733509
-
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
-
Tang R, Cohen S, Perrot JY, Faussat AM, Zuany-Amorim C, Marjanovic Z, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009;9:199.
-
(2009)
BMC Cancer
, vol.9
, pp. 199
-
-
Tang, R.1
Cohen, S.2
Perrot, J.Y.3
Faussat, A.M.4
Zuany-Amorim, C.5
Marjanovic, Z.6
-
44
-
-
84896776546
-
Trastuzumab emtansine: Mechanisms of action and drug resistance
-
Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014;16:R22.
-
(2014)
Breast Cancer Res
, vol.16
, pp. R22
-
-
Barok, M.1
Joensuu, H.2
Isola, J.3
-
45
-
-
84865749390
-
Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure
-
Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, et al. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012;53: 2051-3.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 2051-2053
-
-
Nathwani, N.1
Krishnan, A.Y.2
Huang, Q.3
Kim, Y.4
Karanes, C.5
Smith, E.P.6
-
46
-
-
84987754704
-
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding
-
Aug 17. [Epub ahead of print]
-
Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding. J Cutan Pathol. 2016 Aug 17. [Epub ahead of print].
-
(2016)
J Cutan Pathol
-
-
Al-Rohil, R.N.1
Torres-Cabala, C.A.2
Patel, A.3
Tetzlaff, M.T.4
Ivan, D.5
Nagarajan, P.6
-
47
-
-
84887068994
-
Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
-
Owen SC, Patel N, Logie J, Pan G, Persson H, Moffat J, et al. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release 2013;172:395-404.
-
(2013)
J Control Release
, vol.172
, pp. 395-404
-
-
Owen, S.C.1
Patel, N.2
Logie, J.3
Pan, G.4
Persson, H.5
Moffat, J.6
-
48
-
-
33744537358
-
Lysosomal trafficking and cysteine proteasemetabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30-Auristatin conjugates
-
Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine proteasemetabolism confer targetspecific cytotoxicity by peptide-linked anti-CD30-Auristatin conjugates. J Biol Chem 2006;281:10540-7.
-
(2006)
J Biol Chem
, vol.281
, pp. 10540-10547
-
-
Sutherland, M.S.1
Sanderson, R.J.2
Gordon, K.A.3
Andreyka, J.4
Cerveny, C.G.5
Yu, C.6
-
49
-
-
85008349488
-
Caveolaemediated endocytosis as a novel mechanism of resistance to T-DM1 ADC [abstract]
-
Apr 16-20; New Orleans, LA.; New Orleans, LA: Philadelphia (PA): AACR 2016. Abstract 2113
-
SungM, Tan X, Hosselet C, Cinque M, Upeslacis E, Golas J, et al. Caveolaemediated endocytosis as a novel mechanism of resistance to T-DM1 ADC [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.; New Orleans, LA: Philadelphia (PA): AACR; 2016. Abstract 2113.
-
(2016)
Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Annual Meeting of the American Association for Cancer Research
-
-
Sung, M.1
Tan, X.2
Hosselet, C.3
Cinque, M.4
Upeslacis, E.5
Golas, J.6
-
50
-
-
33746095034
-
Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
-
Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 2006;5:1474-82.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 1474-1482
-
-
Smith, L.M.1
Nesterova, A.2
Alley, S.C.3
Torgov, M.Y.4
Carter, P.J.5
-
52
-
-
0035017308
-
Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-Transport pathway to the ER
-
Pelkmans L, Kartenbeck J, Helenius A.Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-Transport pathway to the ER. Nat Cell Biol 2001;3:473-83.
-
(2001)
Nat Cell Biol
, vol.3
, pp. 473-483
-
-
Pelkmans, L.1
Kartenbeck, J.2
Helenius, A.3
-
53
-
-
84940486817
-
Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1)
-
Chung YC, Kuo JF, Wei WC, Chang KJ, Chao WT. Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1). PLoS ONE 2015;10:e0133072.
-
(2015)
PLoS ONE
, vol.10
, pp. e0133072
-
-
Chung, Y.C.1
Kuo, J.F.2
Wei, W.C.3
Chang, K.J.4
Chao, W.T.5
-
54
-
-
56449129810
-
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
-
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
-
(2008)
Cancer Res
, vol.68
, pp. 9280-9290
-
-
Lewis Phillips, G.D.1
Li, G.2
Dugger, D.L.3
Crocker, L.M.4
Parsons, K.L.5
Mai, E.6
-
55
-
-
31544441685
-
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
-
Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
-
(2006)
Bioconjug Chem
, vol.17
, pp. 114-124
-
-
Doronina, S.O.1
Mendelsohn, B.A.2
Bovee, T.D.3
Cerveny, C.G.4
Alley, S.C.5
Meyer, D.L.6
-
56
-
-
79959700509
-
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
-
Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 347-356
-
-
Junttila, T.T.1
Li, G.2
Parsons, K.3
Phillips, G.L.4
Sliwkowski, M.X.5
-
57
-
-
84955450087
-
SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm
-
Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res 2015;75:5329-40.
-
(2015)
Cancer Res
, vol.75
, pp. 5329-5340
-
-
Hamblett, K.J.1
Jacob, A.P.2
Gurgel, J.L.3
Tometsko, M.E.4
Rock, B.M.5
Patel, S.K.6
-
58
-
-
74849117382
-
Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers
-
Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, et al. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat 2010;120:47-57.
-
(2010)
Breast Cancer Res Treat
, vol.120
, pp. 47-57
-
-
Hamel, S.1
Bouchard, A.2
Ferrario, C.3
Hassan, S.4
Aguilar-Mahecha, A.5
Buchanan, M.6
-
59
-
-
70149109569
-
Novel mechanismof lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL
-
Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanismof lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009;69:6871-8.
-
(2009)
Cancer Res
, vol.69
, pp. 6871-6878
-
-
Liu, L.1
Greger, J.2
Shi, H.3
Liu, Y.4
Greshock, J.5
Annan, R.6
-
60
-
-
84892724922
-
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy
-
Lewis Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2014;20:456-68.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 456-468
-
-
Lewis Phillips, G.D.1
Fields, C.T.2
Li, G.3
Dowbenko, D.4
Schaefer, G.5
Miller, K.6
-
61
-
-
70350494468
-
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
-
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009;114:2721-9.
-
(2009)
Blood
, vol.114
, pp. 2721-2729
-
-
Dornan, D.1
Bennett, F.2
Chen, Y.3
Dennis, M.4
Eaton, D.5
Elkins, K.6
-
62
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
-
(2004)
Cancer Cell
, vol.6
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
Tan, M.4
Esteva, F.J.5
Sahin, A.A.6
-
63
-
-
84980338826
-
Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer
-
Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino E, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 2016;22:3755-63.
-
(2016)
Clin Cancer Res
, vol.22
, pp. 3755-3763
-
-
Baselga, J.1
Lewis Phillips, G.D.2
Verma, S.3
Ro, J.4
Huober, J.5
Guardino, E.6
-
64
-
-
84969745074
-
Intratumoral payload release influences the potency and bystander-killing effects of antibody-drug conjugates in preclinical models
-
Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intratumoral payload release influences the potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 2016;76:2710-9.
-
(2016)
Cancer Res
, vol.76
, pp. 2710-2719
-
-
Li, F.1
Emmerton, K.K.2
Jonas, M.3
Zhang, X.4
Miyamoto, J.B.5
Setter, J.R.6
-
65
-
-
84942898855
-
Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions
-
Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, et al. Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin Cancer Res 2015;21:4165-73.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 4165-4173
-
-
Damelin, M.1
Bankovich, A.2
Park, A.3
Aguilar, J.4
Anderson, W.5
Santaguida, M.6
-
66
-
-
84958843614
-
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
-
Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol 2016;102:1-6.
-
(2016)
Biochem Pharmacol
, vol.102
, pp. 1-6
-
-
Gerber, H.P.1
Sapra, P.2
Loganzo, F.3
May, C.4
|